Tebideutorexant: Difference between revisions
CSV import |
CSV import |
||
| Line 3: | Line 3: | ||
| verifiedfields = changed | | verifiedfields = changed | ||
| verifiedrevid = 123456789 | | verifiedrevid = 123456789 | ||
| IUPAC_name = (2S)-2-[[4-(5-chloro-2-methylphenyl)piperazin-1-yl]methyl]-N-[(2S)-1- | | IUPAC_name = (2S)-2-[[4-(5-chloro-2-methylphenyl)piperazin-1-yl]methyl]-N-[(2S)-1-methyl-2-phenylpropan-2-yl]butanamide | ||
| image = JNJ-61393215.svg | | image = JNJ-61393215.svg | ||
| image2 = | | image2 = | ||
| Line 11: | Line 11: | ||
}} | }} | ||
'''Tebideutorexant''' is a [[dual orexin receptor antagonist]] (DORA) | '''Tebideutorexant''' (development code '''JNJ-61393215''') is a [[dual orexin receptor antagonist]] (DORA) under investigation for the treatment of [[insomnia]] and other sleep disorders. It is being developed by [[Janssen Pharmaceuticals]], a subsidiary of [[Johnson & Johnson]]. | ||
==Mechanism of Action== | ==Mechanism of Action== | ||
Tebideutorexant functions by selectively blocking the activity of the [[orexin]] neuropeptides, which are involved in the regulation of the sleep-wake cycle. Orexins, also known as hypocretins, are produced in the [[hypothalamus]] and promote wakefulness. By antagonizing the [[orexin receptor | Tebideutorexant functions by selectively blocking the activity of the [[orexin]] neuropeptides, which are involved in the regulation of the sleep-wake cycle. Orexins, also known as hypocretins, are produced in the [[hypothalamus]] and promote wakefulness. By antagonizing the [[orexin receptor]]s OX1R and OX2R, tebideutorexant reduces wakefulness and facilitates the onset and maintenance of sleep. | ||
==Pharmacokinetics== | ==Pharmacokinetics== | ||
Tebideutorexant is designed to have a favorable pharmacokinetic profile, with a rapid onset of action and a | Tebideutorexant is designed to have a favorable pharmacokinetic profile, with a rapid onset of action and a half-life that supports once-daily dosing. The drug is metabolized primarily in the liver and excreted through the kidneys. Its pharmacokinetic properties are optimized to minimize next-day residual effects, a common concern with sleep medications. | ||
==Clinical Development== | ==Clinical Development== | ||
Tebideutorexant is currently undergoing clinical trials to evaluate its efficacy and safety in patients with insomnia. | Tebideutorexant is currently undergoing clinical trials to evaluate its efficacy and safety in patients with insomnia. Early-phase studies have shown promising results in terms of sleep induction and maintenance, with a side effect profile that is generally well-tolerated. The ongoing trials aim to further establish the therapeutic potential of tebideutorexant in comparison to existing treatments. | ||
==Potential Benefits== | ==Potential Benefits== | ||
The development of tebideutorexant is part of a broader effort to provide new treatment options for insomnia that have fewer side effects than traditional [[benzodiazepines]] and [[non-benzodiazepine]] sleep aids. As a DORA, tebideutorexant may offer advantages such as reduced risk of dependency and a lower incidence of cognitive impairment. | |||
==Related | ==Related Pages== | ||
* [[Orexin receptor antagonist]] | * [[Orexin receptor antagonist]] | ||
* [[Insomnia]] | * [[Insomnia]] | ||
* [[Sleep disorder]] | * [[Sleep disorder]] | ||
* [[Janssen Pharmaceuticals]] | |||
[[Category:Orexin receptor antagonists]] | [[Category:Orexin receptor antagonists]] | ||
[[Category:Experimental drugs]] | [[Category:Experimental drugs]] | ||
[[Category:Sleep disorders]] | |||
Latest revision as of 06:12, 5 March 2025
A dual orexin receptor antagonist
{{Drugbox
| verifiedfields = changed
| verifiedrevid = 123456789
| IUPAC_name = (2S)-2-[[4-(5-chloro-2-methylphenyl)piperazin-1-yl]methyl]-N-[(2S)-1-methyl-2-phenylpropan-2-yl]butanamide
| image = JNJ-61393215.svg
| image2 =
| width = 200
| alt =
| caption = Chemical structure of Tebideutorexant
}}
Tebideutorexant (development code JNJ-61393215) is a dual orexin receptor antagonist (DORA) under investigation for the treatment of insomnia and other sleep disorders. It is being developed by Janssen Pharmaceuticals, a subsidiary of Johnson & Johnson.
Mechanism of Action[edit]
Tebideutorexant functions by selectively blocking the activity of the orexin neuropeptides, which are involved in the regulation of the sleep-wake cycle. Orexins, also known as hypocretins, are produced in the hypothalamus and promote wakefulness. By antagonizing the orexin receptors OX1R and OX2R, tebideutorexant reduces wakefulness and facilitates the onset and maintenance of sleep.
Pharmacokinetics[edit]
Tebideutorexant is designed to have a favorable pharmacokinetic profile, with a rapid onset of action and a half-life that supports once-daily dosing. The drug is metabolized primarily in the liver and excreted through the kidneys. Its pharmacokinetic properties are optimized to minimize next-day residual effects, a common concern with sleep medications.
Clinical Development[edit]
Tebideutorexant is currently undergoing clinical trials to evaluate its efficacy and safety in patients with insomnia. Early-phase studies have shown promising results in terms of sleep induction and maintenance, with a side effect profile that is generally well-tolerated. The ongoing trials aim to further establish the therapeutic potential of tebideutorexant in comparison to existing treatments.
Potential Benefits[edit]
The development of tebideutorexant is part of a broader effort to provide new treatment options for insomnia that have fewer side effects than traditional benzodiazepines and non-benzodiazepine sleep aids. As a DORA, tebideutorexant may offer advantages such as reduced risk of dependency and a lower incidence of cognitive impairment.
